Structure modification: a successful tool for prodrug design

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Albert A. Chemical aspects of selective toxicity. Nature 182(4633), 421–423 (1958).
  Medline CASGoogle Scholar
• 2. Mishra AP, Chandra S, Tiwari R, Srivastava A, Tiwari G. Therapeutic potential of prodrugs towards targeted drug delivery. Open Med. Chem. J. 12(1), 111–123 (2018).
  Medline CASGoogle Scholar
• 3. Cho S, Yoon Y-R. Understanding the pharmacokinetics of prodrug and metabolite. Transl. Clin. Pharmacol. 26(1), 1 (2018).
  MedlineGoogle Scholar
• 4. Ita KB. Prodrugs for transdermal drug delivery–trends and challenges. J. Drug Target. 24(8), 671–678 (2016).
  Medline CASGoogle Scholar
• 5. Jornada D, dos Santos Fernandes G, Chiba D, de Melo T, dos Santos J, Chung M. The prodrug approach: a successful tool for improving drug solubility. Molecules 21(1), 42 (2015).
  MedlineGoogle Scholar
• 6. Deng C, Liu J, Zhang W. Structural modification in anesthetic drug development for prodrugs and soft drugs. Front. Pharmacol. 13, 923353 (2022).
  Medline CASGoogle Scholar
• 7. Markovic M, Ben-Shabat S, Dahan A. Prodrugs for improved drug delivery: lessons learned from recently developed and marketed products. Pharmaceutics 12(11), 1031 (2020).
  Medline CASGoogle Scholar
• 8. Meng Z, Lv Q, Lu J et al. Prodrug strategies for paclitaxel. Int. J. Mol. Sci. 17(5), 796 (2016).
  MedlineGoogle Scholar
• 9. Hamada Y. Recent progress in prodrug design strategies based on generally applicable modifications. Bioorg. Med. Chem. Lett. 27(8), 1627–1632 (2017).
  Medline CASGoogle Scholar
• 10. Zaro JL. Lipid-based drug carriers for prodrugs to enhance drug delivery. AAPS J. 17(1), 83–92 (2015). •• Describes the lipid internal absorption process and the importance of lipidic prodrug design.
  Medline CASGoogle Scholar
• 11. Lambert DM. Rationale and applications of lipids as prodrug carriers. Eur. J. Pharm. Sci. 11, S15–S27 (2000).
  Medline CASGoogle Scholar
• 12. Dahan A, Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur. J. Pharm. Sci. 24(4), 381–388 (2005).
  Medline CASGoogle Scholar
• 13. Managuli RS, Raut SY, Reddy MS, Mutalik S. Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs. Expert Opin. Drug Deliv. 15(8), 787–804 (2018).
  Medline CASGoogle Scholar
• 14. Fukumura R, Sukhbaatar A, Mishra R, Sakamoto M, Mori S, Kodama T. Study of the physicochemical properties of drugs suitable for administration using a lymphatic drug delivery system. Cancer Sci. 112(5), 1735–1745 (2021).
  Medline CASGoogle Scholar
• 15. Yáñez JA, Wang SWJ, Knemeyer IW, Wirth MA, Alton KB. Intestinal lymphatic transport for drug delivery. Adv. Drug Deliv. Rev. 63(10–11), 923–942 (2011).
  Medline CASGoogle Scholar
• 16. Dahan A, Duvdevani R, Shapiro I, Elmann A, Finkelstein E, Hoffman A. The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J. Control. Release 126, 1–9 (2008). • Reviews the mechanism and historical development of phospholipid prodrugs.
  Medline CASGoogle Scholar
• 17. Markovic M, Ben-Shabat S, Keinan S, Aponick A, Zimmermann EM, Dahan A. Lipidic prodrug approach for improved oral drug delivery and therapy. Med. Res. Rev. 39(2), 579–607 (2019).
  MedlineGoogle Scholar
• 18. Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 4(4), CD000543 (2016).
  MedlineGoogle Scholar
• 19. Krzyzak M, Gupta A, Antonov E, Mulrooney SM. Mesalamine associated bradycardia. Cureus 10(4), e2425 (2018).
  MedlineGoogle Scholar
• 20. Kandula M. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases. Int. Immunopharmacol. 40, 443–451 (2016).
  Medline CASGoogle Scholar
• 21. Spoelstra S, Sikorskii A, Majumder A, Burhenn P, Schueller M, Given B. Oral anticancer agents: an intervention to promote medication adherence and symptom management. Clin. J. Oncol. Nurs. 21(2), 157–160 (2017).
  MedlineGoogle Scholar
• 22. Deng T, Mao X, Xiao Y, Yang Z, Zheng X, Jiang Z-X. Monodisperse oligoethylene glycols modified camptothecin, 10-hydroxycamptothecin and sn38 prodrugs. Bioorg. Med. Chem. Lett. 29(4), 581–584 (2019).
  Medline CASGoogle Scholar
• 23. Bala V, Rao S, Bateman E, Keefe D, Wang S, Prestidge CA. Enabling oral SN38-based chemotherapy with a combined lipophilic prodrug and self-microemulsifying drug delivery system. Mol. Pharm. 13(10), 3518–3525 (2016).
  Medline CASGoogle Scholar
• 24. Porter CJH, Charman WN. Uptake of drugs into the intestinal lymphatics after oral administration. Adv. Drug Deliv. Rev. 25(1), 71–89 (1997).
  CASGoogle Scholar
• 25. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 6(3), 231–248 (2007).
  Medline CASGoogle Scholar
• 26. Paalvast Y, de Boer JF, Groen AK. Developments in intestinal cholesterol transport and triglyceride absorption. Curr. Opin. Lipidol. 28(3), 248–254 (2017).
  Medline CASGoogle Scholar
• 27. Trevaskis NL, Kaminskas LM, Porter CJH. From sewer to saviour–targeting the lymphatic system to promote drug exposure and activity. Nat. Rev. Drug Discov. 14(11), 781–803 (2015).
  Medline CASGoogle Scholar
• 28. Seremeta KP, Tur MIR, Pérez SM et al. Spray-dried didanosine-loaded polymeric particles for enhanced oral bioavailability. Colloids Surf. B Biointerfaces 123, 515–523 (2014).
  Medline CASGoogle Scholar
• 29. Lalanne M, Paci A, Andrieux K et al. Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV. Bioorg. Med. Chem. Lett. 17(8), 2237–2240 (2007).
  Medline CASGoogle Scholar
• 30. Zhang X, Zhao H, Horney J et al. Testosterone deficiency, long-term testosterone therapy, and inflammation. J. Cardiovasc. Pharmacol. Ther. 26(6), 638–647 (2021).
  Medline CASGoogle Scholar
• 31. Hu L, Quach T, Han S et al. Glyceride-mimetic prodrugs incorporating self-immolative spacers promote lymphatic transport, avoid first-pass metabolism, and enhance oral bioavailability. Angew Chem. Int. Ed. 55(44), 13700–13705 (2016).
  Medline CASGoogle Scholar
• 32. Tian C, Guo J, Wang G et al. Efficient intestinal digestion and on site tumor-bioactivation are the two important determinants for chylomicron-mediated lymph-targeting triglyceride-mimetic docetaxel oral prodrugs. Adv. Sci. 6(24), 1901810 (2019).
  CASGoogle Scholar
• 33. Wang L, Feng T, Su Z, Pi C, Wei Y, Zhao L. Latest research progress on anticancer effect of baicalin and its aglycone baicalein. Arch. Pharm. Res. 45(8), 535–557 (2022).
  Medline CASGoogle Scholar
• 34. Wang L, Ma Q. Clinical benefits and pharmacology of scutellarin: a comprehensive review. Pharmacol. Ther. 190, 105–127 (2018).
  Medline CASGoogle Scholar
• 35. Wang X, Zhang C, Han N et al. Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinally. DRUG Deliv. 28(1), 1664–1672 (2021).
  Medline CASGoogle Scholar
• 36. Han S, Quach T, Hu L et al. The impact of conjugation position and linker chemistry on the lymphatic transport of a series of glyceride and phospholipid mimetic prodrugs. J. Pharm. Sci. 110(1), 489–499 (2021).
  Medline CASGoogle Scholar
• 37. Markovic M, Ben-Shabat S, Keinan S, Aponick A, Zimmermann E, Dahan A. Prospects and challenges of phospholipid-based prodrugs. Pharmaceutics 10(4), 210 (2018).
  Medline CASGoogle Scholar
• 38. Hostetler KY, Beadle JR, Hornbuckle WE et al. Antiviral activities of oral 1-O-hexadecylpropanediol-3-phosphoacyclovir and acyclovir in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob. Agents Chemother. 44(7), 1964–1969 (2000).
  Medline CASGoogle Scholar
• 39. Markovic M, Ben-Shabat S, Aponick A, Zimmermann EM, Dahan A. Lipids and lipid-processing pathways in drug delivery and therapeutics. Int. J. Mol. Sci. 21(9), 3248 (2020).
  Medline CASGoogle Scholar
• 40. Mauerhofer C, Philippova M, Oskolkova OV, Bochkov VN. Hormetic and anti-inflammatory properties of oxidized phospholipids. Mol. Aspects Med. 49, 78–90 (2016).
  Medline CASGoogle Scholar
• 41. Markovic M, Abramov-Harpaz K, Regev C et al. Prodrug-based targeting approach for inflammatory bowel diseases therapy: mechanistic study of phospholipid- linker-cyclosporine PLA2-mediated activation. Int. J. Mol. Sci. 23(5), 2673 (2022).
  Medline CASGoogle Scholar
• 42. Sanches BMA, Ferreira EI. Is prodrug design an approach to increase water solubility? Int. J. Pharm. 568, 118498 (2019). •• Describes the classification and development of water-soluble prodrugs, providing numerous ideas for prodrug design.
  Medline CASGoogle Scholar
• 43. Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. Nat. Rev. Drug Discov. 17(8), 559–587 (2018).
  Medline CASGoogle Scholar
• 44. Williams HD, Trevaskis NL, Charman SA et al. Strategies to address low drug solubility in discovery and development. Pharmacol. Rev. 65(1), 315–499 (2013).
  MedlineGoogle Scholar
• 45. Hayashi Y, Skwarczynski M, Hamada Y, Sohma Y, Kimura T, Kiso Y. A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: design and synthesis of isotaxel. J. Med. Chem. 46(18), 3782–3784 (2003).
  Medline CASGoogle Scholar
• 46. Cros-Perrial E, Saulnier S, Raza MZ et al. Cytotoxic and antitumoral activity of N-(9H-purin-6-yl) benzamide derivatives and related water-soluble prodrugs. Curr. Mol. Pharmacol. 15(6), 883–894 (2022).
  Medline CASGoogle Scholar
• 47. Phimmachanh M, Han JZR, O'Donnell YEI, Latham SL, Croucher DR. Histone deacetylases and histone deacetylase inhibitors in neuroblastoma. Front. Cell Dev. Biol. 8, 578770 (2020).
  MedlineGoogle Scholar
• 48. Li J, Zhu Y, Xie M, Zhang Q, Du W. Design, synthesis, and biological evaluation of target water-soluble hydroxamic acid-based HDACi derivatives as prodrugs. Chem. Biol. Drug Des. 94(4), 1760–1767 (2019).
  Medline CASGoogle Scholar
• 49. Livermore DM, Mushtaq S, Warner M, Woodford N. Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteria. J. Antimicrob. Chemother. 69(4), 1050–1056 (2014).
  Medline CASGoogle Scholar
• 50. Ho JM-W, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. Can. Med. Assoc. J. 183(16), 1851–1858 (2011).
  MedlineGoogle Scholar
• 51. Wang X, Borges CA, Ning X et al. A trimethoprim conjugate of thiomaltose has enhanced antibacterial efficacy in vivo. Bioconjug. Chem. 29(5), 1729–1735 (2018).
  Medline CASGoogle Scholar
• 52. Niu G, Tan H. Nucleoside antibiotics: biosynthesis, regulation, and biotechnology. Trends Microbiol. 23(2), 110–119 (2015).
  Medline CASGoogle Scholar
• 53. Negrya SD, Jasko MV, Solyev PN et al. Synthesis of water-soluble prodrugs of 5-modified 2′-deoxyuridines and their antibacterial activity. J. Antibiot. (Tokyo) 73(4), 236–246 (2020).
  Medline CASGoogle Scholar
• 54. Kovanda LL, Maher R, Hope WW. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis. Expert Rev. Clin. Pharmacol. 9(7), 887–897 (2016).
  Medline CASGoogle Scholar
• 55. Zhang X, Lin Y, Gillies RJ. Tumor pH and its measurement. J. Nucl. Med. 51(8), 1167–1170 (2010).
  Medline CASGoogle Scholar
• 56. Corbet C, Feron O. Tumour acidosis: from the passenger to the driver's seat. Nat. Rev. Cancer 17(10), 577–593 (2017).
  Medline CASGoogle Scholar
• 57. Parks SK, Chiche J, Pouyssegur J. pH control mechanisms of tumor survival and growth. J. Cell. Physiol. 226(2), 299–308 (2011). • Describes the mechanisms of pH-sensitive prodrugs.
  Medline CASGoogle Scholar
• 58. Kanamala M, Wilson WR, Yang M, Palmer BD, Wu Z. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review. Biomaterials 85, 152–167 (2016).
  Medline CASGoogle Scholar
• 59. Aichhorn S, Linhardt A, Halfmann A et al. A pH-sensitive macromolecular prodrug as TLR7/8 targeting immune response modifier. Chem. Eur. J. 23(70), 17721–17726 (2017).
  Medline CASGoogle Scholar
• 60. Ma Z, Liu J, Li X et al. Hydroxycamptothecin (HCPT)-loaded PEGlated lipid–polymer hybrid nanoparticles for effective delivery of HCPT: qbD-based development and evaluation. Drug Deliv. Transl. Res. 12(1), 306–324 (2022).
  Medline CASGoogle Scholar
• 61. Lv F, Liu D, Cong H, Shen Y, Yu B. Synthesis, self-assembly and drug release behaviors of a bottlebrush polymer-HCPT prodrug for tumor chemotherapy. Colloids Surf. B Biointerfaces 181, 278–284 (2019).
  Medline CASGoogle Scholar
• 62. Liu Y, Li D, Guo X et al. A pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting. Int. J. Nanomedicine 12, 2227–2242 (2017).
  Medline CASGoogle Scholar
• 63. Toffoli G, Hadla M, Corona G et al. Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin. Nanomedicine 10(19), 2963–2971 (2015).
  Medline CASGoogle Scholar
• 64. González-Méndez I, Solano JD, Porcu P, Ruiu A, Rojas-Aguirre Y, Rivera E. Optimized synthesis, characterization and in vitro systematic evaluation of adamantane-doxorubicin prodrugs sensitive to pH in breast cancer cells. J. Mol. Struct. 1177, 143–151 (2019).
  CASGoogle Scholar
• 65. Krasnovskaya OO, Malinnikov VM, Dashkova NS et al. Thiourea modified doxorubicin: a perspective pH-sensitive prodrug. Bioconjug. Chem. 30(3), 741–750 (2019).
  Medline CASGoogle Scholar
• 66. Chamberlain FE, Jones RL, Chawla SP. Aldoxorubicin in soft tissue sarcomas. Future Oncol. 15(13), 1429–1435 (2019).
  Medline CASGoogle Scholar
• 67. Geiszt M, Kopp JB, Varnai P, Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. Proc. Natl Acad. Sci. USA 97(14), 8010–8014 (2000).
  Medline CASGoogle Scholar
• 68. Le Gal K, Schmidt EE, Sayin VI. Cellular redox homeostasis. Antioxidants 10(9), 1377 (2021). • Describes the process of body oxidation and the series of body responds to oxidative stress.
  MedlineGoogle Scholar
• 69. Bedard K, Krause K-H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87(1), 245–313 (2007).
  Medline CASGoogle Scholar
• 70. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 408(6809), 239–247 (2000).
  Medline CASGoogle Scholar
• 71. D'Autréaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol. 8(10), 813–824 (2007).
  MedlineGoogle Scholar
• 72. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8(7), 579–591 (2009).
  Medline CASGoogle Scholar
• 73. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid. Redox Signal. 20(7), 1126–1167 (2014). • Summarizes and provides insight into advances in rReactive oxygen species-responsive prodrugs.
  Medline CASGoogle Scholar
• 74. Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother. 58(1), 39–46 (2004).
  Medline CASGoogle Scholar
• 75. Wang P, Gong Q, Hu J, Li X, Zhang X. Reactive oxygen species (ROS)-responsive prodrugs, probes, and theranostic prodrugs: applications in the ROS-related diseases. J. Med. Chem. 64(1), 298–325 (2021).
  Medline CASGoogle Scholar
• 76. Stubelius A, Lee S, Almutairi A. The chemistry of boronic acids in nanomaterials for drug delivery. Acc. Chem. Res. 52(11), 3108–3119 (2019).
  Medline CASGoogle Scholar
• 77. Perez C, Monserrat J-P, Chen Y, Cohen SM. Exploring hydrogen peroxide responsive thiazolidinone-based prodrugs. Chem. Commun. 51(33), 7116–7119 (2015).
  Medline CASGoogle Scholar
• 78. Li X, Wu S, Dong G et al. Natural product evodiamine with borate trigger unit: discovery of potent antitumor agents against colon cancer. ACS Med. Chem. Lett. 11(4), 439–444 (2020).
  Medline CASGoogle Scholar
• 79. Lee D, Park S, Bae S et al. Hydrogen peroxide-activatable antioxidant prodrug as a targeted therapeutic agent for ischemia-reperfusion injury. Sci. Rep. 5(1), 16592 (2015).
  MedlineGoogle Scholar
• 80. Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine 86(3), 301–307 (2019).
  Medline CASGoogle Scholar
• 81. Previtali V, Petrovic K, Peiró Cadahía J, Troelsen NS, Clausen MH. Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis. Bioorg. Med. Chem. 28(2), 115247 (2020).
  Medline CASGoogle Scholar
• 82. Andersen NS, Peiró Cadahía J, Previtali V et al. Methotrexate prodrugs sensitive to reactive oxygen species for the improved treatment of rheumatoid arthritis. Eur. J. Med. Chem. 156, 738–746 (2018).
  Medline CASGoogle Scholar
• 83. Dahan A, Markovic M, Aponick A, Zimmermann EM. The prospects of lipidic prodrugs: an old approach with an emerging future. Future Med. Chem. 8(17), 3918–3928 (2020).
  Google Scholar
• 84. Luo C, Sun J, Liu D et al. Self-assembled redox dual-responsive prodrug-nanosystem formed by single thioether-bridged paclitaxel-fatty acid conjugate for cancer chemotherapy. Nano Lett. 16(9), 5401–5408 (2016).
  Medline CASGoogle Scholar
• 85. Lu L, Li B, Lin C et al. Redox-responsive amphiphilic camptothecin prodrug nanoparticles for targeted liver tumor therapy. J. Mater. Chem. B 8(17), 3918–3928 (2020).
  Medline CASGoogle Scholar
• 86. Liu J, Cao C. Evaluation of a GSH-targeting prodrug via a sulfonamide-induced “integrative” platform for selective cancer therapy. Analyst 145(14), 4901–4905 (2020).
  Medline CASGoogle Scholar
• 87. Kong F, Liang Z, Luan D, Liu X, Xu K, Tang B. A glutathione (GSH)-responsive near-infrared (NIR) theranostic prodrug for cancer therapy and imaging. Anal. Chem. 88(12), 6450–6456 (2016).
  Medline CASGoogle Scholar
• 88. Feng W, Gao C, Liu W et al. A novel anticancer theranostic pro-prodrug based on hypoxia and photo sequential control. Chem Commun. 52(60), 9434–9437 (2016).
  Medline CASGoogle Scholar
• 89. Yang Z, Lin H, Huang J et al. A gadolinium-complex-based theranostic prodrug for in vivo tumour-targeted magnetic resonance imaging and therapy. Chem. Commun. Camb. Engl. 55(31), 4546–4549 (2019).
  Medline CASGoogle Scholar
• 90. Li K, Dong W, Qiu L et al. A new GSH-responsive prodrug of 5-aminolevulinic acid for photodiagnosis and photodynamic therapy of tumors. Eur. J. Med. Chem. 181, 111582 (2019).
  Medline CASGoogle Scholar
• 91. Whang C-H, Yoo E, Hur SK, Kim KS, Kim D, Jo S. A highly GSH-sensitive SN-38 prodrug with an “OFF-to-ON” fluorescence switch as a bifunctional anticancer agent. Chem. Commun. 54(65), 9031–9034 (2018).
  Medline CASGoogle Scholar
• 92. Wang D, Zhou N, Zhang N et al. Facile preparation of pH/redox dual-responsive biodegradable polyphosphazene prodrugs for effective cancer chemotherapy. Colloids Surf. B Biointerfaces 200, 111573 (2021).
  Medline CASGoogle Scholar
• 93. Sun I-C, Yoon HY, Lim D-K, Kim K. Recent trends in in situ enzyme-activatable prodrugs for targeted cancer therapy. Bioconjug. Chem. 31(4), 1012–1024 (2020). • Describes the mechanisms and development of enzyme-activated prodrugs.
  Medline CASGoogle Scholar
• 94. Zhang X, Li X, Li Z et al. An NAD(P)H:quinone oxidoreductase 1 responsive and self-immolative prodrug of 5-fluorouracil for safe and effective cancer therapy. Org. Lett. 20(12), 3635–3638 (2018).
  Medline CASGoogle Scholar
• 95. Wang X, Nakamoto T, Dulińska-Molak I, Kawazoe N, Chen G. Regulating the stemness of mesenchymal stem cells by tuning micropattern features. J. Mater. Chem. B 4(1), 37–45 (2016).
  Medline CASGoogle Scholar
• 96. Xiao M, Sun W, Fan J et al. Aminopeptidase-N-activated theranostic prodrug for NIR tracking of local tumor chemotherapy. Adv. Funct. Mater. 28(47), 1805128 (2018).
  Google Scholar
• 97. Shi N-Q, Gao W, Xiang B, Qi X-R. Enhancing cellular uptake of activable cell-penetrating peptide–doxorubicin conjugate by enzymatic cleavage. Int. J. Nanomedicine 7, 1613–1621 (2012).
  Medline CASGoogle Scholar